Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules

Huan He¹, Wenwen Wu², Yi Zhang¹, Meng Zhang¹, Ning Sun¹, Libo Zhao¹* and Xiaoling Wang¹*

¹Clinical Research Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China, ²Department of Pharmacy, Children’s Hospital of Nanjing Medical University, Nanjing, China

Background: The response time-course information of biologics and small targeted molecules for the treatment of moderate to severe plaque psoriasis which helps clinicians to understand the onset of action and maintenance of effect are unclear. Quantitative information about the efficacy comparison of different systemic agents are needed.

Methods: Model-based meta-analysis was conducted and longitudinal models were developed by applying two clinical end points commonly reported in the clinical trials of psoriasis: the proportion of patients achieving ≥75% reduction from baseline Psoriasis Area and Severity Index score (PASI75) and the proportion of patients achieving ≥90% reduction from baseline Psoriasis Area and Severity Index score (PASI90).

Results: A total of 80 trials of thirteen biological agents and four small targeted molecules covering 235 treatment arms and 40323 patients with moderate to severe plaque psoriasis were included in this analysis. The drugs were divided into five classes of biologics and three classes of small molecules. Two longitudinal models of PASI75 and PASI90 were used to describe the time-varying drug effect and dose-effect relationship. The typical response-time courses for PASI75 and PASI90 increased over time and finally reached to the platform. For PASI75 end point at week 12, of all the therapeutic drugs, risankizumab administered as 150 mg at week 0, week 4, and q12w showed the most efficacious with PASI75 was 85.95% (95%CI, 75.71–92.60%), followed by ixekizumab administered as 160 mg at week 0, and q4w with PASI75 was 85.9% (95%CI, 76.12–92.79%). As for PASI90 end point at week 12, ixekizumab 160 mg at week 0, and q4w showed the greatest percentage of person achieved PASI90 (67.2%; 95%CI, 49.91–77.2%), followed by risankizumab 150 mg at week 0, week 4, and q12w (65.5%; 95%CI, 47.8–75.7%). What’s more, the risankizumab provided the highest response of PASI90 at week 16 and week 24.

Conclusions: This study provided a quantitative efficacy comparison of 17 systemic agents for psoriasis in term of efficacy only and that safety was not considered. Risankizumab and ixekizumab showed superiority for both the two end points.

References: He H, Wu W, Zhang Y, Zhang M, Sun N, Zhao L and Wang X (2021) Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules. Front. Pharmacol. 12:586827. doi: 10.3389/fphar.2021.586827
INTRODUCTION

Psoriasis is a common, chronic, immune-mediated inflammatory skin disease which has a high prevalence worldwide (Boehncke and Schon, 2015; Harden et al., 2015). The prevalence of psoriasis in adults varied from 0.91 to 8.5% between countries (Parisi et al., 2013; Rungapiromnan et al., 2020). It is characterized by chronic inflammatory skin lesions with pruritic, well-demarcated, erythematous and scaly plaques combined with a substantial disease burden which affects quality of life (Goff et al., 2015; Cai et al., 2017; Ohtsuki et al., 2019). Treatment options for psoriasis include topical agents, phototherapy and systemic medications such as small targeted molecules and biologics (Menter et al., 2011). The invention of biological agents has greatly improved the treatment outcomes of psoriasis, including inhibitors of tumor necrosis factor (TNF)-α, interleukin (IL)-17, and IL-12/23 (Papp et al., 2008; Saurat et al., 2008; Barker et al., 2011; Paul et al., 2015; Gordon et al., 2016).

There has been rapid development of novel biologic agents for the treatment of moderate-to-severe plaque psoriasis over the past 2 years. IL-23 which is a heterodimer composed of a unique p19 subunit and an associated p40 subunit shared with IL-12 plays a crucial role in the pathogenesis of psoriasis (Chen et al., 2017; Girolomoni et al., 2017). Ustekinumab, one of the IL-12/23 inhibitors which targets the p40 subunit common to both IL-12 and -23 has proved effective in the treatment of psoriasis (Tsai et al., 2011). Recent two years, a new class of biologics for moderate-to-severe plaque psoriasis in adults which targeted the p19 subunit specific to IL-23 were approved by Food and Drug Administration (FDA) (McKeage and Duggan, 2019). The monoclonal antibody IL-23 inhibitors include guselkumab, tildrakizumab and risankizumab (Gordon et al., 2018; Reich et al., 2017; Reich et al., 2017). The TNF-α and IL-17 inhibitors for the treatment of moderate to severe psoriasis included adalimumab, infliximab, etanercept, certolizumab, secukinumab, ixekizumab, and brodalumab. However, it can be challenging for clinicians to determine how the systemic medications compare with one another.

Several meta-analyses (Armstrong et al., 2020; Erichsen et al., 2020; Warren et al., 2020) were conducted to indirectly compare the relative efficacies of approved biologic agents. However, there are some limitations of the published studies. One of the major limitations is that the efficacy of biologics was assessed at one time point (pooling week 12 or 16 together) in different studies which is the disadvantage of traditional meta-analysis and network meta-analysis method. It can’t provide the time-course response information which helps clinicians to understand the full response profile for different compounds and/or placebo which includes the onset of action and maintenance of effect. Second, the existing meta-analysis covered not all the current systemic agents as eleven biologics including four TNF-α inhibitors, one IL-12/23 inhibitor, three IL-23 inhibitors and three IL-17 inhibitors have been approved for the treatment of moderate-to-severe psoriasis, and some small targeted molecules such as Janus kinase (JAK) inhibitors are investigated.

In order to overcome the problems mentioned above, a novel model-based meta-analysis in psoriasis was conducted. Longitudinal model-based meta-analysis is a meta-analysis that explicitly incorporates the effect of dose and duration using standard pharmacology models and assumptions (Mandra et al., 2011). By encompassing longitudinal data from the literature, it allows the comparison of the effect-time course among different treatment and could provide accurate assessment of the drug response (Checchio et al., 2017). Therefore, it could offer more quantitative information about the data than the traditional and network meta-analyses.

The objectives of our study were to assess the relative efficacy of three IL-23 inhibitors for treatment of psoriasis and provide quantitative information about the comparison of different systemic agents including those approved, discontinued and those under investigation by using longitudinal model-based meta-analysis. Two longitudinal models were developed by applying two clinical end points commonly reported in the clinical trials of psoriasis: the proportion of patients achieving ≥75% reduction from baseline Psoriasis Area and Severity Index score (PASI75) and the proportion of patients achieving ≥90% reduction from baseline Psoriasis Area and Severity Index score (PASI90).

METHODS

Database Development

A comprehensive search of clinical trials was conducted using PubMed, Cochrane, Embase, and ClinicalTrials.gov websites. The search keywords were as follows: moderate to severe plaque psoriasis, adalimumab, etanercept, certolizumab, ustekinumab, briakinumab, guselkumab, tildrakizumab, risankizumab, secukinumab, ixekizumab, brodalumab, apremilast, tofacitinib, baricitinib, alefacept, methotrexate and randomized controlled trial. The cutoff date for the search was July 18, 2019. The articles about psoriasis from the reference lists of prior reviews were also screened.

Inclusion criteria of studies were as following: (i) randomized placebo- or active-controlled trials published in English; (ii) trials including patients which was diagnosed with moderate to severe plaque psoriasis and treated with biologics or small targeted molecules; (iii) studies reported the end point PASI75 (≥75% reduction from baseline Psoriasis Area and Severity Index score) or PASI90 (≥90% reduction from baseline Psoriasis Area and Severity Index score).

For each eligible study, relevant data were extracted including drug name, groups, dose, number of patients, time, efficacy outcomes and subject characteristics. Only the first period data of a crossover trial was included in our analysis. The data of
PASI75 and PASI90 of all the published doses were extracted from articles as well as from tables. If efficacy results were presented as a graph, the data were captured by using the GetData Graph Digitizer (V2.25). Two authors (Huan He and Wenwen Wu) independently reviewed the studies and extracted the end point data. Disagreements were settled by a third author (Yi Zhang). In addition, normalization of different dose regimens was conducted to pool the same drug efficacy data.

**Model Development**

After graphical exploration of the data, the longitudinal model of PASI75 and PASI90 were developed to describe the dose-effect and time-effect relationships for each drug. All the doses were used for the modelization. The methodology of modeling was reported previously (Checchio et al., 2017; Wu et al., 2019). The structure of longitudinal model was shown below:

\[
N_{\text{response,ijt}} \sim \text{binomial} \left( N_{ij}, P(\text{response})_{ijt} \right) \tag{1}
\]

\[
P(\text{response})_{ijt} = g(E_0 + E_{\text{drug}}) \tag{2}
\]

\[
g = \frac{1}{1 + e^{-(E_0 + E_{\text{drug}})}} \tag{3}
\]

Where response represents the end points PASI75 (≥75% reduction from baseline Psoriasis Area and Severity Index score) or PASI90 (≥90% reduction from baseline Psoriasis Area and Severity Index score). The \( N_{\text{response,ijt}} \) represents the number of patients achieving PASI75 or PASI90 at \( rth \) time in treatment arm \( j \) of trial \( i \). It follows a binomial distribution with probability \( P(\text{response}) \) and sample size \( N_{ij} \).

The \( g \) is the inverse logit function to restrict the treatment effect, which is the sum of placebo effect \( (E_0) \) and the drug effect \( (E_{\text{drug}}) \) to probability scale of a range of 0–1.

The placebo effect \( (E_0) \) was described by the parameter intercept \( (\text{BSL}) \), asymptote \( (A) \) and rate constant of placebo \( (\text{kpbo}) \) (Eq. 4).

\[
E_0 = \text{BSL} + A \cdot \left( 1 - e^{-k_{\text{pbo}} \cdot \text{time} \cdot \exp(\theta)} \right) \tag{4}
\]

Drug effect \( (E_{\text{drug}}) \) is a function dependent on dose, time, fixed-effect model parameters, and trial covariates \( X \). The potential time-varying drug effect was described by an exponential model and the dose-response relationship function was described by a sigmoidal \( E_{\text{max}} \) model (Eq. 5).

\[
E_{\text{drug}} = \frac{E_{\text{max}} \cdot (1 - e^{-k \cdot \text{time}}) \cdot \text{dose}^\theta}{\text{dose}^\theta + ED_{50}} \tag{5}
\]

where \( E_{\text{max}} \) represents the maximum response for each drug, the parameter \( k \) is the rate constant describing onset of drug effect, \( ED_{50} \) is dose achieving 50% of maximal response. These parameters were estimated for each drug separately. For those drugs with limited dose regimes or without noticeable dose-response, the parameter \( ED_{50} \) was estimated as an unreasonable value or failure. Therefore, the \( ED_{50} \) was fixed to 0 which assumes different dose of this drug have same efficacy if a better model fit was achieved. The \( ED_{50} \) is set to 0 means that the drug effect is depended on time and \( E_{\text{max}} \) without a dose-response relationship. The Hill coefficient \( (\theta) \) was fixed to 1 in the model because there was not sufficient dose–response information available for each drug.

The inter-study variability was added to the structure model parameter by using exponential formula (Eq. 6) if minimization of the model was successful.

\[
P_{ij} = P_j \times e^{\eta_i} \tag{6}
\]

where \( P_j \) and \( P_{ij} \) represent the typical value of \( jth \) population prediction of the corresponding model parameter and \( ith \) individual \( jth \) parameter. The inter-study variability \( (\eta_i) \) was assumed to follow a log-normal distribution with a mean of 0 and a variance of \( \sigma^2 \). The residual error model \( (e) \) was added which is normally distributed with a mean of 0 and a variance of \( \sigma^2 \) (Eq. 7). In addition, weight based on the standard error of fitted values was introduced to the error model (Eq. 8).

\[
\text{Obs}_{ijt} = P_{ijt} + \text{Weight} \times e \tag{7}
\]

\[
\text{Weight} = \frac{P_{ao} \cdot (1 - P_{ao})}{N_{ij} \times \sigma^2} \tag{8}
\]

where \( P_{ijt} \) and \( \text{Obs}_{ijt} \) represents the predicted and observed probability of 75% or 90% improvement in PASI scores at \( rth \) time in treatment arm \( j \) of trial \( i \). \( N_{ij} \) is the sample size in each arm of each trial. This setting ensured that large studies had a small weight on parameter estimating.

According to previous publication (Checchio et al., 2017), body weight was an important covariate. Therefore, body weight was included in the model if a better model fit was achieved, as described in Eq. 9.

\[
\text{Covariate}_{\text{effect}} = \left( \frac{\text{Covariate}}{\text{mean (covariate)}} \right)^\theta \tag{9}
\]

where \( \theta \) is the parameter describe the quantitative relationship between covariate and model parameter. If body weight of a study could not obtain, it was set to the median data of the analysis data set.

**Model Evaluation**

After model establishment, the goodness-of-fit plots and precisions of the parameter estimates were used to describe the adequacy of the final PASI75 and PASI90 longitudinal model. A visual predictive check (VPC) was used to assess the predictive ability of the final model. A total of 1,000 simulations of the final longitudinal model were performed. The VPC graphically showed the observations and different percentiles of simulated predictions (2.5th, median, and 97.5th percentiles).

**Simulation**

Base on the final longitudinal model, 1,000 simulations were conducted to generate the drug response at different time point. The results at week 12 were visualized as median and the 2.5th and 97.5th percentiles.
Analysis Software
The model development and simulation were performed by using NONMEM (v. 7.3) with first-order conditional estimation method. The plots were generated in R (v. 3.5) and Rstudio (v. 1.1.453).

RESULTS
Characteristics of Included Studies
The analysis of this study included a total of 80 trials, covering 235 treatment arms and 40,323 patients. The flow chart of the process screening the included studies is presented in Figure 1. All trials were conducted in patients with moderate to severe plaque psoriasis. Among all the treatment arms, PASI75 end point was reported in 233 arms and PASI90 was reported in 224 arms. An outline of the included trials was summarized in Table 1. Detailed information and references are shown in the Supplementary Materials S1.

The drugs included in the analysis contained thirteen biological agents and four small targeted molecules. According to the types of drug targets, it can be divided into the following categories: TNF-α inhibitors (adalimumab, infliximab, etanercept and certolizumab pegol), IL-12/23 inhibitors (ustekinumab and briakinumab), IL-23 inhibitors (guselkumab, tildrakizumab and risankizumab), IL-17 inhibitors (secukinumab, ixekizumab and brodalumab), phosphodiesterase 4 inhibitor (apremilast), Janus kinase inhibitors (tofacitinib and baricitinib), CD2 antagonist (alefacept) and dihydrofolate reductase inhibitor (methotrexate). All drugs were incorporated in the PASI75 longitudinal model. However, alefacept was not included in the PASI90 longitudinal model because of insufficient data.

PASI75 Model and Typical Drug Efficacies
The PASI75 longitudinal model established in this study could well describe the time-varying drug effect and dose-response relationship. The parameter estimates of drugs for the PASI75 model are provided in Table 2. In the structural model, $E_{\text{drug}}$ is an exponential function dependent on time. The parameter $E_{\text{max}}$ represents the maximum efficacy, and the parameter $k$ is the rate constant describing the onset of each drug. The $E_{\text{max}}$ for apremilast was fixed, otherwise the estimation for apremilast showed larger RSE%. For each of the drug, the parameter $k$ was estimated with an acceptable estimation accuracy. $ED_{50}$ (dose achieving 50% of maximal effect) showed the potency of each drug. For risankizumab, alefacept and methotrexate, the dose-response relationships were not obvious. Therefore, the $ED_{50}$ for these drugs was fixed to 0. For all the drugs except apremilast, the dose regimen is higher than $ED_{50}$. Take adalimumab for example, the $ED_{50}$ value was estimated to be 23.1 mg and the clinical dosage is 40 mg every 2 weeks which means the drug effect is easy to access maximum effect. The placebo effect for PASI75 model was also estimated which was shown in Supplementary Table S1. Body weight effect was included in the parameter $A$ (Asymptote of placebo effect) in the PASI75 placebo effect model which resulted in a better model fit.
| Drug | Trials | Patients | Route (regimen) | Percentage of male (%) | Weight (kg) | Age (year) | Disease duration (years) | Body surface area involved (%) | Baseline PASI | Total Arms | Arms with PASI75 | Arms with PASI90 |
|------|--------|----------|----------------|------------------------|------------|------------|------------------------|--------------------------------|--------------|-----------|----------------|----------------|
| TNF-α inhibitor | | | | | | | | | | |
| Adalimumab | 9 | 2,407 | s.c. (40 mg, 80 mg q2w) | 70.5 (64.8, 84.2) | 86.55 (67.4, 98) | 44.05 (42.9, 50) | 17.6 (11.6, 21) | 95.05 (25, 48.3) | 20.95 (14.5, 20.4) | 12 | 12 | 12 |
| Infliximab | 7 | 1923 | i.v. (3 mg/kg q2, 6) i.v. (5 mg/kg q2, 6, q4w) | 69 (62.9, 73.7) | 84.5 (88.2, 92) | 44.1 (39.4, 46.3) | 18.1 (14.2, 21.5) | 28.85 (25, 45.6) | 20.4 (17.8, 31.9) | 9 | 9 | 9 |
| Etanercept | 21 | 4,556 | s.c. (25 mg, 50 mg b.i.w) | 66 (54, 76.2) | 86.35 (74.1, 96.9) | 45 (38.6, 55.3) | 18.5 (15.2, 23.5) | 26.5 (21.3, 33.6) | 18.45 (11.1, 23.2) | 25 | 23 | 21 |
| Certolizumab pegol | 4 | 810 | s.c. (400 mg q2, 4, 200 mg q2) s.c. (400 mg q2w) | 68.35 (49.4, 75) | 90.75 (63.1, 97.8) | 44.95 (43.6, 47.7) | 18.7 (16.6, 21) | 26.05 (21.4, 28.4) | 20.45 (18.4, 22) | 8 | 8 | 8 |
| IL-12/23 inhibitor | | | | | | | | | | |
| Ustekinumab | 11 | 3,212 | s.c. (45 mg, 90 mg q2, q12w) | 68 (63.6, 82.9) | 90.3 (89.9, 93.8) | 45 (40.1, 46.8) | 18.7 (11.9, 20.3) | 27.1 (20.9, 47) | 20.1 (18.2, 30.1) | 15 | 15 | 15 |
| Brokinumb | 6 | 1,660 | s.c. (200 mg, 4, 100 mg q4w) | 71.05 (61, 81) | 93.1 (86.1, 96.1) | 44.95 (43, 46) | 18.3 (16.1, 24) | 25.25 (19.8, 20.7) | 8 | 8 | 8 |
| IL-23 inhibitor | | | | | | | | | | |
| Guselkumab | 4 | 810 | s.c. (400 mg q2, 4, 200 mg q4w) | 70 (69, 79) | 91.2 (73, 92) | 48.65 (45.5, 53.3) | NA | 26.3 (21.8, 41.6) | 20.5 (19.6, 26.6) | 8 | 8 | 8 |
| Seckinumab | 5 | 1,710 | s.c. (150 mg, 300 mg q4, 1, 2, 3, 4, q4w) | 66 (50, 70) | 92 (85.8, 97) | 46 (42.7, 48) | 18 (13, 21) | 26.7 (21.26) | 19.9 (17.2, 21) | 11 | 11 | 11 |
| Brodalumab | 5 | 2,585 | s.c. (90 mg, 160 mg q4w) | 72 (65, 85) | 90 (72.5, 92) | 45 (42.1, 46.4) | 19 (13.2, 20.7) | 27 (21.3, 43.7) | 20.3 (17.9, 28.5) | 13 | 13 | 13 |
| PDE4 inhibitor | | | | | | | | | | |
| Apremilast | 6 | 1,525 | p.o. (10 mg, 20 mg, 30 mg b.i.d.) | 65.8 (57, 83.5) | 90.65 (70.1, 95.9) | 45.9 (44.1, 52.2) | 19.15 (12.6, 20.7) | 26.3 (20.7, 32) | 19 (18.1, 22) | 10 | 10 | 8 |
| JAK inhibitor | | | | | | | | | | |
| Tolactinum | 6 | 2,557 | p.o. (img, 10 mg b.i.d.) | 72 (59.2, 81.8) | 85 (66.6, 93.1) | 44 (40.7, 50.9) | 16 (13.4, 17) | 29.8 (24, 43.1) | 21.2 (19.3, 26.9) | 13 | 13 | 13 |
| Baricitinibc | 1 | 237 | p.o. (2 mg, 4 mg, 8 mg, 10 mg q2w) | 72.9 (71.9, 75) | 91.15 (89.8, 94.5) | 47.4 (47, 47.8) | 16.6 (15, 19.9) | 28.4 (25.4, 30.8) | 20.4 (19.1, 24) | 4 | 4 | 4 |
| CD2 antagonist | | | | | | | | | | |
| Alefacept | 1 | 339 | i.m. (10 mg, 15 mg q2w) | 71 (56.2, 87.2) | 90.4 (72.5, 89.2) | 45 (42.1, 46.4) | 19 (13.2, 20.7) | 27 (21.3, 43.7) | 20.3 (17.9, 28.5) | 13 | 13 | 13 |
| Apremilast | 6 | 1,525 | p.o. (10 mg, 20 mg, 30 mg b.i.d.) | 65.8 (57, 83.5) | 90.65 (70.1, 95.9) | 45.9 (44.1, 52.2) | 19.15 (12.6, 20.7) | 26.3 (20.7, 32) | 19 (18.1, 22) | 10 | 10 | 8 |
| JAK inhibitor | | | | | | | | | | |
| Tolactinumc | 6 | 2,557 | p.o. (img, 10 mg b.i.d.) | 72 (59.2, 81.8) | 85 (66.6, 93.1) | 44 (40.7, 50.9) | 16 (13.4, 17) | 29.8 (24, 43.1) | 21.2 (19.3, 26.9) | 13 | 13 | 13 |
| Baricitinibc | 1 | 237 | p.o. (2 mg, 4 mg, 8 mg, 10 mg q2w) | 72.9 (71.9, 75) | 91.15 (89.8, 94.5) | 47.4 (47, 47.8) | 16.6 (15, 19.9) | 28.4 (25.4, 30.8) | 20.4 (19.1, 24) | 4 | 4 | 4 |
| CD2 antagonist | | | | | | | | | | |
| Alefacept | 1 | 339 | i.m. (10 mg, 15 mg q2w) | 71 (56.2, 87.2) | 90.4 (72.5, 89.2) | 45 (42.1, 46.4) | 19 (13.2, 20.7) | 27 (21.3, 43.7) | 20.3 (17.9, 28.5) | 13 | 13 | 13 |

PASI, Psoriasis Area and Severity Index score; PASI75, ≥75% reduction from baseline Psoriasis Area and Severity Index score; PASI90, ≥90% reduction from baseline Psoriasis Area and Severity Index score; TNF, tumor necrosis factor; IL, interleukin; PDE, phosphodiesterase; JAK, Janus kinase; NA, not available; s. c., subcutaneous; p. o., oral; qw, once weekly; q2w, once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks; biw, twice weekly; qd, once daily.

aData are shown as median (range).
bInvestigational.
cDiscontinued. All other drugs are approved.
The typical drug efficacies deserved more attention for clinicians. Based on the final PASI75 longitudinal model, the simulated typical PASI75 response-time curves under clinical dose were shown in Figure 2. For each drug, the predicted response-time relationship could cover most of the observed data. As can be seen from the curves, the PASI75 response increased over time and finally reached to 0 subsequently. The time-varying drug effect and placebo effect model which was consistent as PASI75 model. The placebo effect for PASI90 model was estimated and the results were listed in Supplementary Table S2. Body weight showed an effect on placebo component A of the PASI90 placebo effect model which was consistent as PASI75 model.

The final PASI90 model was used to simulate the percentage of person achieve PASI90 at different time point, assuming a typical body weight with 90 kg. The typical response-time course and dose–effect correlation of PASI90 endpoint were well described by an exponential model and $E_{\text{max}}$ model, respectively. The final estimated parameters of PASI90 longitudinal model are listed in Table 4. The dose-response difference of ustekinumab was not significant and estimating $ED_{50}$ resulted in a poor model estimation accuracy. Therefore, $ED_{50}$ for ustekinumab was fixed to 0 subsequently. The $ED_{50}$ values of guselkumab, tildrakizumab and risankizumab were 2.95 mg (95% CI, 2.578–3.322), 7.16 mg (95% CI, 3.534–10.786) and 13.3 mg (95% CI, 7.067–19.533), respectively. The placebo effect for PASI90 model was estimated and the results were listed in Table 5. The simulation results of PASI90 response at week 24 not only in IL-23 inhibitors but also in all the treatment.

## Table 2: Final parameter estimates of PASI75 longitudinal model.

| Drug                  | $E_{\text{max}}$ (Estimate (RSE%)) | 95% CI       | $ED_{50}$ (Estimate (RSE%)) | 95% CI       | $k$ (Estimate (RSE%)) | 95% CI       |
|-----------------------|-----------------------------------|--------------|-----------------------------|--------------|-----------------------|--------------|
| Adalimumab            | 5.84 (3.7)                        | (5.417, 6.263) | 23.1 (10)                  | (18.572, 27.628) | 0.463 (14.1)        | (0.335, 0.591) |
| Infliximab            | 4.46 (7)                          | (3.845, 5.075) | 0.462 (48.9)               | (0.019, 0.905) | 0.663 (13)           | (0.494, 0.832) |
| Etanercept            | 4.34 (10)                         | (3.485, 5.195) | 21.5 (30.2)                | (8.76, 34.24)  | 0.282 (10.7)         | (0.223, 0.341) |
| Certolizumab pegol    | 3.95 (3.4)                        | (3.689, 4.211) | 10.1 (70.2)                | (−3.796, 23.996) | 0.327 (21.7)        | (0.188, 0.466) |
| Ustekinumab           | 4.33 (4.4)                        | (3.966, 4.704) | 6.38 (41.5)                | (1.186, 11.574) | 0.241 (10.5)        | (0.192, 0.29)  |
| Brodalumab            | 4.94 (5)                          | (4.458, 5.422) | 12.1 (27)                  | (5.691, 18.509) | 0.317 (8.4)         | (0.265, 0.369) |
| Gusekumab             | 4.63 (2.6)                        | (4.416, 4.844) | 2.75 (4)                   | (2.536, 2.964)  | 0.294 (11.1)        | (0.223, 0.358) |
| Tildrakizumab         | 3.81 (4)                          | (3.51, 4.11)   | 4.63 (9.5)                 | (3.772, 5.486)  | 0.229 (10.5)        | (0.192, 0.276) |
| Risankizumab          | 5.05 (1.8)                        | (4.872, 5.228) | 0 FX                      | —             | 0.242 (9.5)         | (0.197, 0.287) |
| Secukinumab           | 5.74 (5.4)                        | (5.136, 6.344) | 69.2 (10.4)                | (55.108, 83.292) | 0.509 (8)          | (0.429, 0.589) |
| Ixekizumab            | 5.05 (2.3)                        | (4.821, 5.279) | 9.74 (12)                  | (7.447, 12.033) | 1.16 (9.2)          | (0.95, 1.37)   |
| Brodalumab            | 7.69 (8.4)                        | (6.345, 9.95)  | 152 (16.6)                 | (102.412, 201.588) | 1.14 (7.5)        | (0.973, 1.307) |
| Apremilast            | 9 FX                             | —             | 98.5 (6.1)                | (86.662, 110.338) | 0.381 (20.8)       | (0.226, 0.536) |
| Tofacitinib           | 4.65 (6.2)                        | (4.089, 5.211) | 4.23 (13.4)                | (3.121, 5.339)  | 0.498 (13.1)       | (0.37, 0.628)  |
| Baricitinib           | 5.63 (19.2)                       | (3.513, 7.747) | 8.4 (20.4)                 | (5.048, 11.752) | 0.24 (42.1)        | (0.042, 0.438) |
| Alefacect             | 1.36 (5.5)                        | (1.231, 1.529) | 0 FX                      | —             | 0.115 (6.8)        | (0.1, 0.13)    |
| Methotrexate          | 2.32 (4.1)                        | (2.133, 2.507) | 0 FX                      | —             | 0.212 (28.9)       | (0.092, 0.302) |

was 57.7% (95%CI, 41.9–68%). Alefacect showed less efficacious than other treatments.
model. Ixekizumab 160 mg 0, q4w showed the greatest percentage of person achieved PASI90 (67.2%; 95%CI, 49.91–77.2%) at week 12, followed by risankizumab 150 mg 0, 4, q12w (65.5%; 95%CI, 47.8–75.7%). The percentage of person achieved PASI90 for brodalumab 210 mg 0, 1, 2, q2w, ixekizumab 160 mg 0, 80 mg q4w, secukinumab 300 mg 0, 1, 2, 3, 4, q4w and guselkumab

FIGURE 2 | The model predicted typical time course of PASI75 response of each drug. Lines are model predictions for average body weight 90 kg subjects. Circles represent the observed efficacy data, and the symbol size is proportional to the sample size. PASI75, ≥75% reduction from baseline Psoriasis Area and Severity Index score.
100 mg 0, 4, q8w were 64.5% (95%CI, 47.31–75%), 62.6% (95%CI, 45.4–74.2%), 62.5% (95%CI, 46.1–73.3%) and 61% (95%CI, 42.5–72.1%), respectively. For the PASI90 end point, the IL-17 inhibitors and IL-23 inhibitors except tildrakizumab were also more effective than other classes of biologics and small molecules. On the whole, the responses of biological agents except etanercept were superior than small molecules which was reflected in the figure. Tofacitinib 10 mg b.i.d. (33.6%; 95%CI, 18.7–44.5%) was the most effective in small molecule drugs. Apremilast showed less efficacious than other treatments.

**Model Evaluation**

The goodness-of-fit plots for the PASI75 and PASI90 model are presented in Supplementary Figures S1–S2, which shows there are not any apparent systematic bias and misspecification. The VPC results for the PASI75 and PASI90 model are shown in Supplementary Figures S3–S4. This VPC plots indicated an adequate predictive ability of the final model.

**DISCUSSION**

Our study presented a quantitative information for the efficacy comparison across seventeen drugs. Two independent longitudinal model-based meta-analyses including two binary end points (PASI75 and PASI90) were carried out to describe the time-varying drug efficacy. PASI75 end point has previously been benchmark to define treatment response in plaque psoriasis clinical trials (Carlin et al., 2004). However, higher standards (complete or near complete clearance of psoriasis) is now a reality with newer biologic therapies. PASI90 or PASI100 were adopted as the new standard for an optimal response in clinical trials (Puig, 2015). In our study, both PASI75 and PASI90 were included which offered a comprehensive understanding of the drug efficacy. The data of PASI100 was not adequate to build a longitudinal model. Clinicians and patients could select their preferred treatments depending on their priorities.

In general, the efficacy trend is similar across these two endpoints: anti-IL-23 and anti-IL-17 treatments except tildrakizumab were the most effective among the classes of biologics and small molecules. Risankizumab administered as 150 mg at week 0, week 4 and q12w and ixekizumab administered as 160 mg at week 0 followed by 160 mg q4w or 80 mg q2w provided the highest response of PASI75 and PSAI90 at week 16 and week 24. The efficacy of risankizumab is superior than adalimumab is observed in our study which is also

**TABLE 3** | Model predicted PASI75 response of treatments at different time points.

| Drug Regimen | Week 4 | Week 8 | Week 12 | Week 16 | Week 24 |
|--------------|--------|--------|---------|---------|---------|
| **PASI75(%)** |        |        |         |         |         |
| **TNF-α inhibitor** |        |        |         |         |         |
| Adalimumab 80 mg 0 40 mg 1 q2w | 21.30  (8.59, 39.20) | 56.96 (36.30, 70.40) | 67.80  (53.70, 77.30) | 71.20 (61.31, 79.90) | 72.80 (65.20, 80.10) |
| Infliximab 5 mg/kg 0 2, 6, q8w | 34.10 (16.60, 55.20) | 67.10 (47.70, 80.20) | 75.65 (62.80, 84.00) | 78.20 (69.40, 85.40) | 79.70 (72.71, 86.40) |
| Etanercept 50 mg b.i.d | 7.98 (2.29, 17.90) | 34.40 (18.70, 48.80) | 49.60 (34.91, 60.20) | 55.00 (43.50, 64.40) | 57.80 (48.30, 66.70) |
| Certolizumab pegol 400 mg 0, 2, 4 200 mg q2w | 15.30 (5.30, 31.20) | 53.15 (33.72, 68.60) | 67.70 (52.61, 77.69) | 71.80 (62.01, 80.40) | 74.00 (67.00, 81.30) |
| **IL-12/23 inhibitor** |        |        |         |         |         |
| Ustekinumab 45 mg 0 4, q12w | 10.75 (3.63, 23.70) | 47.30 (28.10, 61.90) | 65.30 (50.90, 75.80) | 71.20 (61.30, 80.70) | 74.50 (66.60, 81.90) |
| Brodalumab 300 mg 0, 1, 2, 3, 4, q4w | 56.50 (33.50, 76.60) | 80.40 (62.80, 89.40) | 85.90 (76.12, 89.80) | 87.70 (80.50, 90.90) | 88.50 (82.90, 93.90) |
| **IL-17 inhibitor** |        |        |         |         |         |
| Secukinumab 180 mg 0 80 mg q4w | 48.95 (26.90, 70.39) | 75.20 (56.50, 85.80) | 84.60 (77.10, 92.60) | 89.40 (82.90, 94.70) | 91.00 (85.90, 96.00) |
| Brodalumab 210 mg 0, 1, 2, q2w | 22.50 (63.31, 83.90) | 72.50 (53.31, 83.90) | 85.96 (75.71, 92.60) | 89.40 (76.00, 94.70) | 91.00 (79.90, 95.10) |
| **PDE4 inhibitor** |        |        |         |         |         |
| Apremilast 30 mg b.i.d | 5.68 (0.92, 13.90) | 20.30 (9.18, 32.69) | 29.50 (17.50, 39.79) | 33.20 (23.30, 41.70) | 35.30 (27.31, 43.50) |
| **JAK inhibitor** |        |        |         |         |         |
| Tofacitinib 5 mg b.i.d | 9.07 (2.48, 19.49) | 29.00 (14.40, 44.20) | 39.20 (25.90, 50.50) | 42.80 (32.30, 51.60) | 45.10 (36.30, 53.90) |
| Tofacitinib 10 mg b.i.d | 16.30 (5.52, 32.50) | 46.55 (26.50, 62.00) | 57.70 (41.90, 68.00) | 61.60 (50.10, 70.20) | 63.10 (54.41, 72.30) |
| Baricitinib 10 mg qd | 7.34 (1.66, 16.60) | 33.10 (17.10, 46.30) | 48.70 (34.30, 59.50) | 54.80 (44.10, 64.10) | 58.30 (49.91, 67.10) |
| **CD2 antagonist** |        |        |         |         |         |
| Alefacept 10 mg qw | 1.90 (0.5, 5.86) | 7.46 (1.83, 14.50) | 12.90 (5.90, 19.60) | 15.90 (9.40, 23.20) | 19.30 (12.60, 26.20) |
| Dihydrofatty acid reductase inhibitor |        |        |         |         |         |
| Methotrexate 20 mg qw | 4.14 (0.48, 10.50) | 19.00 (7.61, 30.30) | 30.80 (18.51, 42.10) | 36.80 (25.80, 48.30) | 40.10 (31.80, 48.30) |

PASI, Psoriasis Area and Severity Index score; PASI75, ≥75% reduction from baseline Psoriasis Area and Severity Index score; TNF, tumor necrosis factor; IL, interleukin; PDE, phosphodiesterase; JAK, Janus kinase; NA, not available; s.c., subcutaneous; p. o., oral; q.w, once weekly; q2w, once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks; b.i.d, twice daily; q.d, once daily.

*aData are shown as median (95% CI).*
supported by a head-to-head trial and a meta-analysis (Reich et al., 2019; Witjes et al., 2020). Superior efficacy of guselkumab, another IL-23 inhibitor, was also predicted compared with adalimumab which is in concert with previous trials (Blauvelt et al., 2017; Reich, et al., 2017). Although our model-based meta-analysis showed a quantitative comparison of risankizumab and IL-17 inhibitors. However, the efficacy of risankizumab compared with IL-17 inhibitors need to demonstrated by head-to-head trials. A direct comparation of risankizumab and secukinumab is ongoing in a phase 3 study (NCT03478787). The targeted therapies for the treatment of moderate-to-severe plaque psoriasis is going through a re-evaluation.

Compared with the conclusions of previous meta-analyses, our study provided different and more detailed rank-order. The comparison about existing meta-analyses including IL-23 inhibitors are summarized in Supplementary Table S3. Apart from common biologicals of IL-17, IL-23 and TNF-α inhibitors (ustekinumab, secukinumab, brodalumab, ixekizumab, 

---

**FIGURE 3** | Ranking of treatments for psoriasis presented as median response rate for PASI75 (A) and PASI90 (B) at week 12 (from high to low). Circles represent the median value and horizontal bars are 95% intervals from model simulation (N = 1,000) assuming average body weight 90 kg; PASI75, ≥75% reduction from baseline Psoriasis Area and Severity Index score; PASI90, ≥90% reduction from baseline Psoriasis Area and Severity Index score; qw, once weekly; q2w, once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks; biw, twice weekly; qd, once daily; b.i.d., twice daily.

**TABLE 4** | Final parameter estimates of PAS90 longitudinal model.

| Drug           | Estimate (RSE%) | 95% CI       | Estimate (RSE%) | 95% CI       | Estimate (RSE%) | 95% CI       |
|----------------|-----------------|--------------|-----------------|--------------|----------------|--------------|
| Adalimumab     | 5.74 (7.6)      | (4.885, 6.595) | 18.3 (25.7)     | (9.088, 27.512) | 0.487 (26.5)   | (0.234, 0.74) |
| Infliximab     | 4.73 (4.6)      | (4.307, 5.153) | 0.689 (23.8)    | (0.398, 1.01)  | 0.802 (25.2)   | (0.249, 1.355) |
| Etanercept     | 5.33 (11.2)     | (4.158, 6.502) | 30.7 (25.3)     | (15.471, 45.929) | 0.181 (12.7)   | (0.136, 0.226) |
| Certolizumab   | 3.99 (4.9)      | (3.606, 4.372) | 8.1 (63.2)      | (–1.335, 18.133) | 0.24 (21.2)    | (0.141, 0.343) |
| Ustekinumab    | 4.06 (3.3)      | (3.796, 4.325) | 9.47 (20.1)     | (5.746, 13.194) | 0.243 (11.6)   | (0.188, 0.298) |
| Brikizumab     | 4.9 (4.9)       | (4.518, 5.282) | 2.95 (6.4)      | (2.578, 3.322)  | 0.341 (14.3)   | (0.245, 0.437) |
| Gusekumab      | 4.78 (3.8)      | (4.427, 5.133) | 7.16 (25.8)     | (3.534, 10.786) | 0.537 (43)     | (0.084, 0.99)  |
| Tildrakizumab  | 3.99 (5.4)      | (3.571, 4.409) | 13.3 (23.9)     | (7.067, 19.533) | 0.252 (45.6)   | (0.027, 0.477) |
| Risankizumab   | 5.56 (2.8)      | (5.252, 5.868) | 79.2 (15.4)     | (55.288, 103.112) | 0.246 (9.4)    | (0.201, 0.291) |
| Secukinumab    | 5.88 (5.1)      | (5.382, 6.578) | 7.02 (15.8)     | (4.844, 9.196)  | 0.467 (16.1)   | (0.32, 0.614)  |
| Ixekizumab     | 5.14 (3.3)      | (4.809, 5.471) | 2.9 (14.1)      | (2.096, 3.704)  | 1.12 (22.5)    | (0.626, 1.614) |
| Brodalumab     | 6.92 (7.7)      | (5.875, 7.965) | 0 FIX           |               | 1.19 (16)      | (0.818, 1.562) |
| Apremilast     | 8.8 FIX         |               | 54.1 (52.3)     | (–1.368, 109.568) | 0.0541 (50.1) | (0.001, 0.107) |
| Tofacitinib    | 4.78 (10.7)     | (3.758, 5.762) | 3.42 (31.9)     | (1.284, 5.556)  | 0.395 (62.8)   | (–0.091, 0.881) |
| Baricitinib    | 4.1 (4.4)       | (3.749, 4.451) | 2.9 (14.1)      | (2.096, 3.704)  | 0.481 (24.7)   | (0.248, 0.714) |
| Methotrexate   | 2.56 (6.6)      | (2.28, 2.84)  | 0 FIX           |               | 0.19 (32.6)    | (0.068, 0.312) |

He et al. Model-Based Meta-Analysis in Psoriasis

Frontiers in Pharmacology | www.frontiersin.org July 2021 | Volume 12 | Article 586827
guselkumab, tildrakizumab, adalimumab, infliximab, etanercept, certolizumab pegol) which were generally reported in these meta-analyses, another four small targeted molecules (apremilast, tofacitinib, baricitinib and methotrexate) were evaluated in our model-based meta-analysis. This is a comprehensive quantitative comparison of systemic medications for moderate

FIGURE 4 | The model predicted typical time course of PASI90 response of each drug. Lines are model predictions for average body weight 90 kg subjects. Circles represent the observed efficacy data, and the symbol size is proportional to the sample size. PASI90, ≥90% reduction from baseline Psoriasis Area and Severity Index score.
to severe plaque psoriasis. Furthermore, the efficacy data at different time were all used by an exponential model to describe the potential time-varying drug effect, whereas the traditional pairwise and network meta-analyses pooled the efficacy data at different time. Our study provided a new insight in the onset of drug response by applying longitudinal data. Next, the dose-response relationships were estimated separately. Finally, in the process of comparing the efficacy data at different time, our study provided a new insight in the onset of drug response by applying longitudinal data.

This study has some advantages. First, our analysis was based on longitudinal model. We provided time-course response of all the agents for the treatment of psoriasis. It has the benefits of model-based meta-analysis such as extracting knowledge from all the time point data and different doses, which is quite different from traditional meta-analysis. A difference may be explored (such as superior of risankizumab) by using the extracted knowledge. Second, our analysis was conducted on the basis of the largest and detailed rank-order at week 12 was visualized clearly.

In conclusion, the model-based meta-analysis provided quantitative information about the efficacy comparation in psoriasis of five classes of biologics and three classes of small molecules with a total of seventeen systemic agents for two end points in term of efficacy only and that safety was not considered. Risankizumab and ixekizumab showed superiority for both the two end points. Further studies about the long-term efficacy are needed.

### Table 5: Model predicted PASI90 response of treatments at different time points.

| Drug Regimen | PASI90(%)a |
|--------------|------------|
|              | Week 4     | Week 8 | Week 12 | Week 16 | Week 24 |
| TNF-a inhibitor |            |        |         |         |         |
| Adalimumab 80 mg 0, 40 mg 1, q2w | 6.10 (0.69, 18.00) | 30.30 (12.10, 48.59) | 43.50 (27.11, 55.00) | 48.05 (35.70, 58.20) | 50.60 (42.70, 59.90) |
| Infliximab 5 mg/kg 0, 2, 6, q8w | 10.40 (2.45, 26.80) | 36.80 (14.81, 54.20) | 49.15 (31.81, 61.00) | 53.40 (40.60, 63.80) | 55.90 (46.80, 65.00) |
| Etanercept 50 mg biw | 1.16 (0, 4.73) | 9.90 (2.90, 20.10) | 22.00 (10.60, 31.00) | 28.96 (18.20, 37.89) | 34.40 (25.90, 42.50) |
| Certolizumab pegol 400 mg 0, 2, 4, 200 mg q2w | 2.29 (0, 7.70) | 20.00 (6.95, 34.40) | 36.50 (21.10, 47.70) | 43.50 (31.51, 53.40) | 47.80 (39.20, 55.80) |
| IL-12/23 inhibitor |            |        |         |         |         |
| Ustekinumab 45 mg 0, 4, q12w | 2.64 (0, 8.55) | 22.90 (8.72, 38.10) | 41.60 (24.91, 58.20) | 48.85 (37.20, 58.10) | 53.20 (45.00, 62.10) |
| Briakinumab 100 mg q4w | 5.83 (0.71, 16.50) | 37.10 (16.14, 54.90) | 54.85 (37.11, 65.90) | 60.80 (48.81, 70.20) | 63.60 (54.40, 71.40) |
| IL-23 inhibitor |            |        |         |         |         |
| Gusekumab 100 mg 0, 4, q8w | 11.7 (0.30, 30.09) | 47.45 (23.60, 65.49) | 61.00 (42.50, 72.10) | 65.40 (52.30, 74.50) | 67.40 (58.70, 75.50) |
| Tildrakizumab 100 mg 0, 4, q12w | 2.21 (0, 6.68) | 18.10 (7.01, 31.10) | 34.80 (19.40, 45.40) | 40.70 (29.90, 50.50) | 44.90 (36.70, 53.90) |
| Risankizumab 150 mg 0, 4, q12w | 5.11 (0.41, 15.60) | 42.15 (19.60, 60.79) | 65.50 (47.80, 75.70) | 72.70 (61.41, 81.40) | 76.70 (69.70, 84.00) |
| IL-17 inhibitor |            |        |         |         |         |
| Secukinumab 300 mg 0, 1, 2, 3, 4, q4w | 10.60 (2.04, 26.30) | 47.95 (23.92, 65.90) | 62.50 (46.10, 73.30) | 66.70 (56.10, 75.80) | 69.30 (61.40, 77.50) |
| Ixekizumab 160 mg 0, q4w | 21.60 (6.91, 47.79) | 55.35 (30.00, 72.70) | 67.20 (49.91, 77.20) | 71.10 (60.10, 79.50) | 73.10 (65.00, 80.60) |
| Ixekizumab 160 mg 0, 2, 4, q4w | 18.40 (5.91, 45.10) | 50.40 (24.01, 67.80) | 62.60 (45.40, 74.20) | 66.95 (55.20, 76.00) | 69.40 (60.71, 77.00) |
| Brodalumab 210 mg 0, 1, 2, q2w | 19.90 (5.81, 44.50) | 52.15 (27.00, 70.49) | 64.50 (47.31, 75.00) | 68.60 (57.30, 78.20) | 70.80 (62.80, 79.00) |
| PDE4 inhibitor |            |        |         |         |         |
| Apremilast 30 mg b.i.d. | 0.38 (0, 2.14) | 2.68 (0, 6.36) | 6.09 (1.45, 11.50) | 9.75 (4.23, 15.30) | 16.40 (9.99, 22.60) |
| JAK inhibitor |            |        |         |         |         |
| Tofacitinib 5 mg b.i.d. | 1.99 (0, 6.88) | 12.00 (3.29, 22.60) | 19.50 (9.94, 29.40) | 23.40 (14.00, 31.70) | 25.10 (17.60, 32.50) |
| Tofacitinib 10 mg b.i.d. | 3.52 (0.03, 10.60) | 21.40 (7.96, 36.40) | 33.60 (18.70, 45.50) | 38.15 (26.80, 47.10) | 40.70 (31.60, 49.10) |
| Baricitinib 10 mg qd | 3.05 (0.08, 10.50) | 17.20 (5.53, 30.10) | 26.20 (13.30, 38.20) | 29.96 (18.90, 38.70) | 32.30 (23.90, 40.60) |
| Dihydrofolate reductase inhibitor |            |        |         |         |         |
| Methotrexate 20 mg qw | 0.85 (0, 3.59) | 6.27 (1.19, 13.80) | 13.05 (5.76, 20.70) | 17.00 (9.42, 24.30) | 20.10 (12.50, 27.10) |

PASI, Psoriasis Area and Severity Index score; PASI90, ≥90% reduction from baseline Psoriasis Area and Severity Index score; TNF, tumor necrosis factor; IL, interleukin; PDE, phosphodiesterase; JAK, Janus kinase; NA, not available; s.c., subcutaneous; p.o., oral; qw, once weekly; q2w, once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks; biw, twice weekly; qd, once daily.

Data are shown as median (95% CI).
still needed to enhance the understanding of the relative drug efficacy and safety.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

**AUTHOR CONTRIBUTIONS**

All authors contributed to the design and implementation of the study. L-BZ and X-LW designed the study. HH wrote the manuscript and I-BZ and X-LW revised it.

**REFERENCES**

Armstrong, A. W., Puig, L., Joshi, A., Skup, M., Williams, D., Li, J., et al. (2020). Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Lager, T., Ohtsuki, M., et al. (2016). Phase 3 Trials of Ixekizumab in Moderate-To-Severe Plaque Psoriasis. *N. Engl. J. Med.*, 375, 345–356. doi:10.1056/NEJMoa1512711

Gordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., et al. (2018). Efficacy and Safety of Risankizumab in Moderate-To-Severe Plaque Psoriasis (UltIMMa-1 and UltIMMa-2): Results from Two Double-Blind, Randomized, Placebo-Controlled and Ustekinumab-Controlled Phase 3 Trials. *Lancet* 392, 650–661. doi:10.1016/S0140-6736(18)31713-6

Harden, J. L., Krueger, J. G., and Bowcock, A. M. (2015). The Immunogenetics of Psoriasis: A Comprehensive Review. *J. Autoimmun.* 64, 66–73. doi:10.1016/j.jaut.2015.07.008

Mandema, J. W., Gibbs, M., Boyd, R. A., Wada, D. R., and Piitser, M. (2011). Model-based Meta-Analysis for Comparative Efficacy and Safety: Application in Drug Development and beyond. *Clin. Pharmacol. Ther.* 90, 766–769. doi:10.1038/clpt.2011.242

McKeage, K., and Duggan, S. (2019). Risankizumab: First Global Approval. *Drugs* 79, 893–900. doi:10.1007/s40265-019-01136-7

Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. L., Gordon, B. K., et al. (2011). Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 6. Guidelines of Care for the Treatment of Psoriasis and Psoriatic Arthritis: Case-Based Presentations and Evidence-Based Conclusions. *J. Am. Acad. Dermatol.* 65, 137–174. doi:10.1016/j.jaad.2010.11.055

Ohtsuki, M., Fujita, H., Watanabe, M., Suzuki, K., Flack, M., Huang, X., et al. (2019). Efficacy and Safety of Risankizumab in Japanese Patients with Moderate to Severe Plaque Psoriasis: Results from the SustalMM Phase 2/3 Trial. *J. Dermatol.* 46, 686–694. doi:10.1111/1346-8138.14941

Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yelding, N., et al. (2008). Efficacy and Safety of Ustekinumab in a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 52-week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2). *Lancet* 371, 1675–1684. doi:10.1016/s0140-6736(08)60726-6

Parisi, R., Symmons, D. P., Griffiths, C. E., Ashcroft, D. M., et al. (2013). Identification, Management of Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence. *J. Invest. Dermatol.* 133, 377–385. doi:10.1038/jid.2012.339

Paul, C., Lacour, J. P., Tedremets, L., Kreutzer, K., Jazayeri, S., Adams, S., et al. (2015). Efficacy, Safety and Usability of Secukinumab Administration by Autoinjector/pen in Psoriasis: A Randomized, Controlled Trial (JUNCTURE). *J. Eur. Acad. Dermatol. Venereol.* 29, 1082–1090. doi:10.1111/jdv.12751

Puig, L. (2015). PASI90 Response: the New Standard in Therapeutic Efficacy for Psoriasis. *J. Eur. Acad. Dermatol. Venereol.* 29, 645–648. doi:10.1111/jdv.12817

Reich, K., Armstrong, A. W., Foley, P., Song, M., Was, I., Randazzo, B., et al. (2017). Efficacy and Safety of Gusekumab, an Anti-interleukin-23 Monoclonal Antibody, Compared with Adalimumab for the Treatment of Patients with

**FUNDING**

This work was supported by grants from National Science and Technology Major Project for Major New Drugs Innovation and Development (2017ZX09304029 and 2018ZX09721003).

**ACKNOWLEDGMENTS**

The authors acknowledge TC for the share of model code.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.586827/full#supplementary-material
Moderate to Severe Psoriasis with Randomized Withdrawal and Retreatment: Results from the Phase III, Double-Blind, Placebo- and Active Comparator-Controlled VOYAGE 2 Trial. *J. Am. Acad. Dermatol.* 76, 418–431. doi:10.1016/j.jaad.2016.11.042

Reich, K., Gooderham, M., Thaçi, D., Crowley, J. J., Ryan, C., Krueger, J. G., et al. (2019). Risankizumab Compared with Adalimumab in Patients with Moderate-To-Severe Plaque Psoriasis (IMMvent): a Randomised, Double-Blind, Active-Comparator-Controlled Phase 3 Trial. *The Lancet* 394, 576–586. doi:10.1016/s0140-6736(19)30952-3

Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaci, D., et al. (2017). Tildrakizumab versus Placebo or Etanercept for Chronic Plaque Psoriasis (reSURFACE 1 and reSURFACE 2): Results from Two Randomised Controlled, Phase 3 Trials. *Lancet* 390, 276–288. doi:10.1016/s0140-6736(17)31279-5

Rungapiromnan, W., Mason, K. J., Lunt, M., McElhone, K., Burden, A. D., Rutter, M. K., et al. (2020). Risk of Major Cardiovascular Events in Patients with Psoriasis Receiving Biologic Therapies: a Prospective Cohort Study. *J. Eur. Acad. Dermatol. Venereol.* 34, 769–778. doi:10.1111/jdv.16018

Saurat, J. H., Stingl, G., Dubertret, L., Papp, K., Langley, R. G., Ortonne, J. P., et al. (2008). Efficacy and Safety Results from the Randomized Controlled Comparative Study of Adalimumab vs. Methotrexate vs. Placebo in Patients with Psoriasis (CHAMPION). *Br. J. Dermatol.* 158, 558–566. doi:10.1111/j.1365-2133.2007.08315.x

Tsai, T. F., Ho, J. C., Song, M., Szapary, P., Guzzo, C., Shen, Y. K., et al. (2011). Efficacy and Safety of Ustekinumab for the Treatment of Moderate-To-Severe Psoriasis: a Phase III, Randomized, Placebo-Controlled Trial in Taiwanese and Korean Patients (PEARL). *J. Dermatol. Sci.* 63, 154–163. doi:10.1016/j.jdermsci.2011.05.005

Warren, R. B., Gooderham, M., Burge, R., Zhu, B., Amato, D., Liu, K. H., et al. (2020). Comparison of Cumulative Clinical Benefits of Biologics for the Treatment of Psoriasis over 16 Weeks: Results from a Network Meta-Analysis. *J. Am. Acad. Dermatol.* 82, 1138–1149. doi:10.1016/j.jaad.2019.12.038

Witjes, H., Khatri, A., Diderichsen, P. M., Mandema, J., and Othman, A. A. (2020). Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority. *Clin. Pharmacol. Ther.* 107, 435–442. doi:10.1002/cpt.1624

Wu, Y., Feng, X., Li, J., Wang, X., Yang, C., and Zhao, L. (2019). Model-Based Meta-Analysis in Ankylosing Spondylitis: A Quantitative Comparison of Biologics and Small Targeted Molecules. *Clin. Pharmacol. Ther.* 105, 1244–1255. doi:10.1002/cpt.1305

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2021 He, Wu, Zhang, Zhang, Sun, Zhao and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*